Mesenchymal stem cell therapy for severe COVID-19
Abstract The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has placed a global public burden on health authorities. Although the virological characteristics and pathogenesis of COVID-19 has been largely clarified, there is currently no s...
Main Authors: | Lei Shi, Lifeng Wang, Ruonan Xu, Chao Zhang, Yunbo Xie, Kai Liu, Tiantian Li, Wei Hu, Cheng Zhen, Fu-Sheng Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-09-01
|
Series: | Signal Transduction and Targeted Therapy |
Online Access: | https://doi.org/10.1038/s41392-021-00754-6 |
Similar Items
-
Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells
by: Lei Shu, et al.
Published: (2020-08-01) -
Mesenchymal stem cells in the treatment of severe COVID-19
by: Santosh Kesari, et al.
Published: (2021-08-01) -
Correction to: Mesenchymal stem cells in the treatment of severe COVID-19
by: Santosh Kesari, et al.
Published: (2021-08-01) -
Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia
by: Zhinian Guo, et al.
Published: (2020-07-01) -
Challenges for Mesenchymal Stem Cell-Based Therapy for COVID-19
by: Li C, et al.
Published: (2020-09-01)